Illumina Files Patent Infringement Suits Against BGI in Sweden and the United Kingdom
Illumina, Inc. (NASDAQ: ILMN) today announced that it has filed two additional patent infringement suits relating to BGI’s sequencing products, including the DNBSeq-400 (also known as MGISeq-2000), DNBSeq-T7, and related chemistry reagents.
The first complaint was filed against MGI Tech Co., Ltd. and Latvia MGI Tech SIA in the High Court of Justice, Chancery Division, Patents Court in the United Kingdom alleging infringement of four patents: EP 1 530 578 B1, EP 1 828 412 B2, EP 2 021 415 B1, and EP 3 002 289 B1. The second complaint was filed against Latvia MGI Tech SIA in the Patent and Market Court in Sweden alleging infringement of EP 3 002 289 B1. The patents cover Illumina’s proprietary sequencing-by-synthesis chemistry.
Related patent suits are pending in Denmark, Germany, Switzerland, Turkey and the United States.
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and follow @illumina .
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AMAZENTIS23.1.2020 21:58:10 CET | Press release
Amazentis Announces the Launch of Timeline™ Cellular Nutrition at the World Economic Forum in Davos
MA-LIONBRIDGE23.1.2020 19:02:07 CET | Press release
Lionbridge Names Corinne Saunders as Managing Director, EMEA
CA-PATIENT-SAFETY23.1.2020 18:36:07 CET | Press release
President Bill Clinton to Keynote 2020 World Patient Safety, Science & Technology Summit
COVANTIS-INITIATIVE23.1.2020 16:02:13 CET | Press release
Covantis initiative announces technology partner - ConsenSys
PATHOQUEST23.1.2020 14:02:09 CET | Press release
PathoQuest’s Paris-based Facility Obtains GLP Certificate for the Company’s Biologics Genomic Quality Control Testing Service
NY-MOODY’S23.1.2020 13:03:04 CET | Press release
Moody’s Acquires RDC, a Leader in Risk and Compliance Intelligence, Data and Software
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom